Ann S La Casce

Learn More
PURPOSE Bendamustine hydrochloride is an alkylating agent with novel mechanisms of action. This phase II multicenter study evaluated the efficacy and toxicity of bendamustine in patients with B-cell non-Hodgkin's lymphoma (NHL) refractory to rituximab. PATIENTS AND METHODS Patients received bendamustine 120 mg/m(2) intravenously on days 1 and 2 of each(More)
  • 1